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Human herpesviruses have previously been implicated in the pathogenesis of Alzheimer’s 
disease (AD) but whether they are causal, facilitating, or confounding factors is yet to be 
established. A total of 50 AD subjects and 52 non-demented (ND) controls were analyzed 
in a multiplex assay for IgG reactivity toward herpes simplex virus (HSV), varicella zoster 
virus (VZV), cytomegalovirus (CMV), and human herpesvirus 6 (HHV-6). The HHV-6 IgG 
reactivity was significantly lower in AD subjects compared to ND controls, whereas there 
were no differences in HSV, VZV, or CMV antibody levels between the groups. Analysis 
of peripheral blood mononuclear cells with a subtype-specific HHV-6 PCR revealed no 
signs of reactivation, as AD and ND subjects presented with comparable HHV-6 DNA 
levels in PBMCs, and all positive samples were of subtype B. Whether HHV-6 is a factor 
in AD remains to be elucidated in future studies.
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inTrODUcTiOn
It has been debated whether infectious agents are causing, triggering, or facilitating the most 
common age-related diseases, such as cardiovascular disease, dementia, diabetes, and cancer. 
Well-proven examples include human papillomavirus, causing the majority of cervical cancers, and 
Helicobacter pylori, causing duodenal ulceration (1, 2), but several other pathogen-disease links have 
been suggested where data are conflicting or controversial.
Human herpesviruses are widely spread in the population, with the seroprevalence of varicella 
zoster virus (VZV), Epstein–Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6 
(HHV-6) increasing rapidly in the first years of life, whereas herpes simplex virus (HSV) infection 
generally occurs at more advanced ages (3–6). HSV types 1 and 2, VZV, and HHV-6A are all neu-
rotropic and can cause acute central nervous system (CNS) illness even in immunocompetent hosts 
(7–10). CMV is less prone to infect neurons but target endothelial cells, microglia, and hematopoietic 
cells, including those that reside in the brain and could therefore have indirect effects through 
immune modulation or inflammatory mediators (11).
Alzheimer’s disease (AD), with approximately 36.5 million people currently affected worldwide, 
is the most common form of dementia, causing substantial suffering for patients and a heavy burden 
on caretakers (12). Whether infectious diseases can be causal, facilitating, or confounding factors in 
the pathogenesis of AD is yet to be established. Studies of AD postmortem brain tissue have shown 
an increased prevalence of HSV-1 DNA in patients carrying the ApoE ϵ4 allele and HHV-6 DNA 
regardless of ApoE genotype (8).
In terms of humoral immune response, it has been shown that serum levels of HSV IgM, but 
not IgG, antibodies correlates with AD (13–15). Furthermore, it has been suggested that there is a 
TaBle 1 | summary of baseline characteristics in patients with 
alzheimer’s disease (aD) and non-demented controls (nD).
continuous data reported as mean (sD) aD (N = 50) nD (N = 52)
Age, years 77.5 (6.9) 74.2 (7.9)
Gender, male/female 28/22 23/29
Mini-Mental State Examination score 19.9 (4.8) NA
APOE ϵ4 allele carriers, hetero-/homozygote 28/4 16/2
NA, not available.
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cumulative correlation between a serologic pattern of multiple 
herpesvirus infections and cognitive decline in patients with vas-
cular disease (16, 17). Also, a connection between CMV and AD 
was made in a combined clinical and postmortem study where 
CMV IgG levels and IFN-γ in cerebrospinal fluid correlated with 
neuropathologic characteristics of AD (18). This is consistent with 
the findings in a previous prospective study, where an increased 
rate of cognitive decline was seen in patients with high levels of 
CMV IgG (19).
We have previously shown that AD patients present with 
a lower frequency of CMV-specific CD8+ T-cells and that 
CMV-seropositive AD patients show a more pro-inflammatory 
peripheral blood mononuclear cell (PBMC) phenotype than 
both CMV-seronegative AD patients and CMV-seropositive 
non-demented (ND) controls (20, 21). In this study, we have 
investigated whether patients with AD present with a differ-
ent herpesvirus-specific serologic pattern compared to ND 
controls, using an in-house multiplex IgG immunoassay with 
antigens generated by lysis of purified virions from infected 
cells. Furthermore, we have investigated whether the differences 
seen in the serologic reactivity pattern could be verified by PCR 
analysis of PBMCs.
MaTerials anD MeThODs
subjects and sampling Procedure
A total of 51 AD patients and 52 ND controls were included 
from a previously described cohort (20). One participant in 
the AD group was excluded due to a change in the diagnosis 
from AD to frontotemporal dementia, rendering a total of 50 
AD subjects and 52 ND controls. Demographics and cognitive 
performance of the study groups is described in Table  1. All 
AD subjects had recently received a clinical AD diagnosis in 
accordance with the NINCDS-ADRDA criteria and DSM-IV 
criteria. Thus, all patients described a clinical picture of AD and 
a CT or MRI scan consistent with the diagnosis, i.e., without 
significant vascular abnormalities. Subjects in the ND control 
group had been recruited via local advertising and did not show 
any frank clinical signs that could suggest the presence of cogni-
tive deficits or complain of any subjective cognitive impairment. 
Blood samples were acquired by venipuncture, performed at the 
Memory Disorder Unit at Uppsala University Hospital. Plasma 
was separated from blood cells through centrifugation, and the 
samples were frozen at −20°C until analyzed. PBMCs were iso-
lated using BD Vacutainer CPT™ Cell Preparation Tubes with 
sodium citrate and frozen in batches of 5 × 106 cells in medium 
consisting of 15% dimethyl sulfoxide and 85% fetal calf serum. 
The dementia status of all study participants were blinded during 
the laboratory work.
This study was carried out in accordance with the Declaration 
of Helsinki. Written informed consent was obtained from all 
study participants, together with consent from a close relative if 
the subject was considered incapable of taking his or her own 
decision. The study was approved (no. 2009/097) by the Regional 
Ethical Review Board in Uppsala, Sweden.
antigens
The following antigens (Advanced Biotechnologies, Eldersburg, 
MD, USA) were used for the analyses: herpes simplex type 1 
(strain MacIntyre, cat. no. 10-145-000, purified by ultracentrifu-
gation, control antigen: VERO cells, cat. no. 10-508-001), CMV 
(strain AD169 purified viral lysate, cat. no. 10-144-000, control 
antigen: human foreskin fibroblasts cells, cat. no. 10-505-001), 
VZV (strain rod, pelleted virus from supernatant from an 
infected culture, cat. no. 10-282-500, control antigen: VERO 
cells), and HHV-6A (GS strain, pelleted virus from supernatant 
of an infected culture, cat. no. 10-241-500, control antigen: 
HSB-2 cells, cat. no. 10-529-001). The purified virions were 
lysed by exposure to the non-ionic detergent Triton-X100 (1% 
w/v) for 10 min at room temperature. Antigens were dialyzed 
overnight against phosphate buffered saline before coupling. 
Coupling to beads at lysine positions of the peptides were made 
using water-soluble carbodiimide according to the procedure 
described by Luminex Corporation. Between 10 and 30 µg of 
protein was used per coupling, which sufficed for approximately 
1,000 tests.
Multiplex immunoassay
All antigens were covalently coupled to carboxylated color-coded 
beads, as previously described by Elfaitouri et al  (22). IgG was 
detected using biotinylated protein G (23). The specificity of the 
antibody detection was confirmed by using 4 µg/ml biotinylated 
monoclonal anti-IgG (BioLegend, San Diego, CA, USA, cat. no. 
409307). Results are expressed as median fluorescent intensity. 
StabilGuard (SurModics, Eden Prairie, MN, USA) was used as 
a sample diluent throughout the process. Samples were diluted 
1:10, including the preparation steps prior to loading the filter 
plate. A final bead concentration of 25 beads/μl was used during 
analysis. All samples and controls were sonicated and vortexed 
for 20 s before being added to the bead mixture.
The standard Luminex protocol for indirect antibody capture 
immunoassay was followed with the previously described adapta-
tions (22). Samples (100 µl) were analyzed on a Luminex® 200™ 
system, in accordance with the manufacturer’s instructions. The 
StarStation (Applied Cytometry, Sheffield, UK) and xPONENT® 
(Luminex Corporation, Austin, TX, USA) software were used to 
analyze the data.
hhV-6 Pcr
In brief, HHV-6 DNA was extracted from 200,000 PBMCs 
using MagNA Pure LC Total Nucleic Acid Isolation Kit—High 
Performance (Roche Diagnostics). HHV-6 DNA quantification 
was performed using a RealStar HHV-6 PCR kit 1.0 (Altona 
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Diagnostics) on an ABI 7500 FAST Real-time PCR instrument 
(Applied Biosystems). The PCR program consisted of 1 cycle at 
95°C in 10 min followed by 45 cycles at 95°C in 15 s and 58°C in 
1 min. To evaluate potential PCR inhibition, an internal control 
was included in each PCR and detected with a JOE-labeled 
IC-specific probe. The PCR method differentiates HHV-6A and 
HHV-6B through a FAM-labeled HHV-6A and a Cy5-labeled 
HHV-6B-specific probe. From the specification provided by the 
PCR kit manufacturer, the analytical sensitivity of the PCR 
assay was calculated to two copies of HHV-6 DNA, but the 
primer and probe sequences are not given. Subtype specificity 
of the assay was confirmed by testing cultured HHV-6A GS 
Strain and HHV6B Z-29 Strain. The specificity of the assay 
was further verified by testing HSV-1, HSV-2, VZV, CMV, 
EBV, HHV-7, HHV-8, BK, and JC virus, parvovirus, hepatitis 
A, B, C, and HIV-1.
statistical analysis
R version 3.0.2 (The R Foundation for Statistical Computing) with 
packages coin (version 1.1.0) and latticeExtra (version 0.6.26) 
was used for statistical analysis and graphical output. AD and 
ND groups were compared using a multivariate Mann–Whitney 
test. Multiplicity adjustment was done using a permutation-based 




All IgG reactivity data were plotted in a matrix of pairwise 
comparisons, revealing no obvious patterns of cross-reactivity 
between the respective sets of antigens (Figure 1). Density plots 
(Figure 2) showed clustering into seronegative and seropositive 
populations for CMV and HSV-1. For HHV-6 and VZV, there 
was no clear separation into subpopulations, most likely due to a 
very high seroprevalence in the study population.
Alzheimer’s disease patients presented with significantly lower 
HHV-6 IgG reactivity compared to ND controls (p = 0.02 after 
multiplicity adjustment, Figure 2). The numerical difference in 
CMV IgG between AD and ND groups failed to reach statistical 
significance (p = 0.28 after multiplicity adjustment). Within the 
AD group, there was no correlation between MMSE score and 
IgG levels for HHV-6 or CMV (Figure 3). Neither were there any 
significant differences between AD and ND groups with respect 
to HSV or VZV IgG levels. Both positive and negative results 
were verified in a logistic regression model including all antibody 
levels, age, and gender.
To assess the correlation between the whole-virus IgG reactiv-
ity in the multiplex assay and microbiologic reference methods, 
a selected set of samples was also analyzed using single-agent 
ELISA kits (Focus Diagnostics HerpeSelect HSV IgG, Vidas 
CMV IgG, Mobitech anti-HHV-6 IgG, and Siemens Enzygnost 
anti-VZV/IgG). The epitopes created through the in-house lysis 
of purified virions in the multiplex assay resulted in differences 
compared to reference methods and illustrated that the assays are 
not directly interchangeable (Figure 4).
hhV-6 Pcr
As the multiplex immunoassay indicated a possible difference 
in HHV-6 humoral immunity between AD and ND groups, we 
proceeded to analyze PBMC samples with a subtype-specific 
quantitative HHV-6 PCR to establish whether there was a differ-
ence in peripheral viral reactivation between groups. A total of 50 
AD and 52 ND subjects were analyzed, rendering 4 HHV-6 DNA-
positive results in the AD group (8%) and 4 in the ND group 
(7.7%). All positive samples were of HHV-6 subtype B. There 
was no clear difference in DNA levels between the two groups 
(Table 2). Two AD and one ND participants presented with DNA 
levels in the 106 copies (per 106 cells) range, most likely related to 
chromosomally integrated HHV-6.
DiscUssiOn
In this study, we illustrate the application of a multiplex 
immunoassay with in-house-generated antigens to compare 
IgG reactivity against four human herpesviruses of which some 
have previously been connected to AD, both seroepidemio-
logically (13–17) and by the presence of viral DNA in AD 
brain tissue (25). Although the assay would need additional 
validation to be useful in a clinical setting for the diagnosis 
of herpesvirus infections, we believe the current results are 
valid for the within-study comparison of humoral herpesvirus 
immunity between AD and ND subjects. Moreover, this alterna-
tive methodological approach could provide new insights in 
addition to the previous studies performed with regular single 
ELISA assays.
The finding that AD subjects have significantly lower levels 
of HHV-6 IgG reactivity compared to ND controls is in contrast 
to the previous findings by Agostini et al., who did not see a cor-
relation between HHV-6 IgG and cognitive performance (26). 
Also, the fact that demented subjects were found to present 
with lower IgG toward an agent in the herpesvirus group is 
different from what is previously known from studies of CMV 
and HSV-1, where cognitive decline has been associated with 
higher antibody levels (14, 15, 19). However, as cell tropism 
differs within the herpesvirus group, the humoral immune 
response could have different effects on the AD pathophysiol-
ogy depending on the type of virus and possibly also the stage 
of disease.
These findings, suggesting an impaired humoral immunity 
against HHV-6, could provide an explanation to the more 
frequent findings of HHV-6 DNA in AD brain tissue, although 
this study does not give any evidence of causality. The work by 
Carbone et al. could however give a hint, as they observed an 
increased risk of progression to AD in the subjects in the control 
group that presented with a positive HHV6 PCR on peripheral 
blood at baseline (25). With an expected seroprevalence of 
HHV-6 close to 100% in these age groups, the differences are 
probably not attributable to total prevalence of chronically 
persistent HHV-6 infection but rather to differences in humoral 
immune response. One could speculate on whether decreased 
antibody levels increase the risk of local CNS HHV-6 reactiva-
tion, elevating the inflammatory response that could enhance 
FigUre 1 | scatter plot matrix. Pairwise plots for all combinations of antigens, comparing antibody distributions for Alzheimer’s disease (AD) and non-demented 
(ND) groups. The overall absence of strong diagonal patterns indicates no obvious cross-reactivity between antibodies.
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AD pathology (27). Other possible explanations include age 
differences between AD and ND groups at the time of primary 
infection or more profound immunologic changes in AD affect-
ing herpesvirus immunity in general.
As there was no difference in HHV-6 DNA in PBMC between 
the groups, and all positive samples were of subtype B, the 
results do not support the hypothesis that peripheral reactiva-
tion of HHV-6 of any subtype is implicated in AD pathogenesis. 
However, as we did not analyze brain tissue samples, we cannot 
exclude local HHV-6 reactivation. These results are in conflict 
with a previous study by Carbone et al. who found HHV-6 DNA 
five times more frequently in peripheral blood leukocytes from 
AD subjects compared to controls (25).
Array-based multiplex techniques have made it possible to 
measure antibodies to many infectious agents simultaneously 
with a small sample volume, allowing a rapid syndrome-
centered overview of pathogen antibodies, and provide better 
control of false-positive reactions due to cross-reactivity than 
what can be achieved with single assays. It has been previ-
ously reported that multiplexing serologic assays can introduce 
negative matrix effects caused by interindividual variations in 
serum lipids, proteins, heterophilic antibodies, and immune 
complexes (28, 29). However, the protocol used in this study 
uses a lower concentration of carrier proteins and has so far 
proven robust. We chose to measure only IgG reactivity as the 
relevance of IgM, especially outside the clinical context of paired 
FigUre 2 | Density plots and empirical cumulative distribution functions (ecDF). Left: density plots of virus-specific antibody levels. The distributions for 
cytomegalovirus (CMV) and herpes simplex virus (HSV)-1 illustrate clustering of subjects into seronegative and seropositive populations. No obvious clustering was 
seen in human herpesvirus 6 (HHV-6) and varicella zoster virus (VZV) plots, as expected when seroprevalence is close to 100%. Right: ECDF plots illustrating that 
Alzheimer’s disease (AD) patients present with lower HHV-6 antibody levels than non-demented (ND) controls (p = 0.02 with Bonferroni-Holm correction).
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sampling in primary infection, which is limited not only by the 
methodological issues mentioned above but also by the natural 
cross-reactivity between different members of the herpesvirus 
group due to their structural similarity that affects IgM more 
than IgG (30, 31).
As the multiplex serologic protocol used in this study has not 
been extensively validated against the gold standard methods used 
in clinical practice, any comparison with these should be made 
with caution. Also, the serologic distinction between HHV-6A 
and HHV-6B is difficult to make due to cross-reactivity, so the 
FigUre 3 | correlation of igg reactivity and cognitive performance in alzheimer’s disease (aD) patients. No correlation could be found between 
cytomegalovirus (CMV) or human herpesvirus 6 (HHV-6) IgG levels and MMSE score. Only AD patients were included.
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FigUre 4 | correlation between multiplex assay and reference methods. The correlation of IgG reactivity between the multiplex assay and standard ELISA is 
low for herpes simplex virus (HSV) (R2 = 0.16) and human herpesvirus 6 (HHV-6) (R2 = 0.22), intermediate for cytomegalovirus (CMV) (R2 = 0.59), and high for 
varicella zoster virus (VZV) (R2 = 0.91).
7Westman et al. Decreased HHV-6 IgG in Alzheimer’s Disease
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identified differences are likely to be driven by a large contribu-
tion of HHV6-B antibodies.
Although several other members of the human herpesvirus 
family have been previously correlated with cognitive decline, we 
could not—with the exception of HHV-6—find any serological 
evidence supporting the hypothesis that infections with HSV, 
VZV, or CMV correlate with AD. The precision of these nega-
tive results is, however, limited by the sample size in this study. 
Whether HHV-6 is involved in the pathogenesis of AD or other 
neurodegenerative diseases remains to be elucidated in future 
studies.
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TaBle 2 | subtype-specific hhV-6 Pcr.
gender age Dementia status hhV-6 Dna subtype
Male 68 Alzheimer’s disease (AD) 4 × 106 B
Male 76 AD 2 × 106 B
Male 80 AD 9 × 103 B
Female 72 AD 8 × 101 B
Female 72 Non-demented (ND) 6 × 101 B
Male 51 ND 2 × 106 B
Male 75 ND 1 × 102 B
Female 75 ND 2 × 104 B
Overview of AD and ND subjects positive for HHV-6 DNA in PBMCs. DNA levels are 
expressed as copies per million cells.
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